Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines

• Published in: Nature communications Vol. 14; no. 1; p. 5312
• Main Authors: Tovar, M, Moreno, Y, Sanz, J
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 01.09.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Bayesian analysis; Chains; Clinical trials; Design factors; Disease transmission; Effectiveness; Epidemiology; Mathematical models; Tuberculosis; Vaccine development; Vaccine efficacy; Vaccines
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-40976-6

Abstract In tuberculosis (TB) vaccine development, multiple factors hinder the design and interpretation of the clinical trials used to estimate vaccine efficacy. The complex transmission chain of TB includes multiple routes to disease, making it hard to link the vaccine efficacy observed in a trial to specific protective mechanisms. Here, we present a Bayesian framework to evaluate the compatibility of different vaccine descriptions with clinical trial outcomes, unlocking impact forecasting from vaccines whose specific mechanisms of action are unknown. Applying our method to the analysis of the M72/AS01 E vaccine trial -conducted on IGRA+ individuals- as a case study, we found that most plausible models for this vaccine needed to include protection against, at least, two over the three possible routes to active TB classically considered in the literature: namely, primary TB, latent TB reactivation and TB upon re-infection. Gathering new data regarding the impact of TB vaccines in various epidemiological settings would be instrumental to improve our model estimates of the underlying mechanisms.